Inari Medical, Inc. (NASDAQ:NARI) has reported a recent transaction involving its Chief Medical Officer, Thomas Tu. According to the latest SEC filing, Tu sold 3,480 shares of common stock on July 16, 2024, at prices ranging from $55.00 to $55.52. The transaction totaled over $191,956, with the weighted average selling price being $55.16 per share.
Following this sale, Tu's direct ownership in the company stands at 309,777 shares of common stock. It's worth noting that the trades were made under a pre-arranged 10b5-1 trading plan, which allows company insiders to set up a predetermined schedule for buying and selling stocks at a time when they are not in possession of material non-public information.
This trading plan had been adopted by Tu on November 11, 2023, providing a structured and compliant way for him to manage his equity in Inari Medical. Such plans are commonly used by corporate executives to avoid any allegations of insider trading, as they demonstrate that the trades were planned in advance and not based on any confidential information.
Investors and market watchers often look to insider transactions as a gauge of management's view of the company's prospects. While the reasons for such sales can vary, they are typically disclosed in a transparent manner to ensure that all market participants have access to the same information.
Inari Medical specializes in the development of medical devices used in the treatment of vascular conditions. The company is known for its innovative approaches to the treatment of conditions such as deep vein thrombosis and pulmonary embolism.
The details of the transaction are publicly available for further review by the SEC staff, the issuer, or any security holder of the issuer, as indicated in the footnotes of the SEC filing.
In other recent news, Inari Medical has been the center of attention following robust Q1 results, with a 23% year-over-year increase in revenue, reaching $143.2 million. This growth was primarily attributed to U.S. core venous thromboembolism (VTE) treatments, leading the company to raise its full-year revenue guidance to between $592.5 million and $602.5 million. The company reported a GAAP operating loss of $17.2 million due to several deal-related expenses. Investment firms including Needham, Truist Securities, Baird, Piper Sandler, and Canaccord Genuity have adjusted their price targets for Inari Medical, reflecting a mix of optimism and caution. The company also plans to penetrate new markets such as China and Japan later this year. In addition, Needham downgraded Inari Medical stock from Buy to Hold due to anticipated rising competition in the venous thrombectomy market. Lastly, Inari Medical has been cooperating with the Department of Justice on a Corporate Integrity Agreement, which has not yet impacted the company commercially.
InvestingPro Insights
As Inari Medical, Inc. (NASDAQ:NARI) navigates the market, recent data from InvestingPro shows a mixed financial landscape for the company. The company's Gross Profit Margin for the last twelve months as of Q1 2024 stands at an impressive 87.67%, indicating a strong ability to translate sales into profit. This aligns with one of the InvestingPro Tips highlighting Inari's impressive gross profit margins, which could be a signal of operational efficiency and a solid product offering.
However, the stock's current P/E Ratio is at -132.93, and the adjusted P/E Ratio for the same period is even lower at -339.84, suggesting that investors are expecting future growth to justify the current share price. Another notable InvestingPro Tip points out that the stock is currently in overbought territory according to the Relative Strength Index (RSI), which might indicate a potential pullback in the near term. This tip could be particularly relevant for investors considering the recent insider selling activity.
On the performance front, Inari Medical has shown significant returns, with a 10.13% price total return over the last week and a 29.03% return over the past month. This type of momentum could capture the attention of investors looking for growth in their portfolios.
For those interested in a deeper dive into Inari Medical's financials and future prospects, InvestingPro provides additional insights and tips. There are 11 more InvestingPro Tips available that can help investors make more informed decisions. Visit https://www.investing.com/pro/NARI and remember to use the coupon code PRONEWS24 to get up to 10% off a yearly Pro and a yearly or biyearly Pro+ subscription.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.